





an Open Access Journal by MDPI

Advances in Targeted Photodynamic Therapy Based on Nanotechnology

Guest Editors:

Dr. Milutin Stepić

Center for Light-Based Research and Technologies Coherence, Department of Atomic Physics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia

Dr. Maja D. Nešić

Center for Light-Based Research and Technologies Coherence, Department of Atomic Physics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia

Deadline for manuscript submissions:

20 August 2024

Message from the Guest Editors

Photodynamic therapy (PDT) is a noncumulative, noninvasive, and selective therapeutic modality exploited treating various types of cancer, infections, inflammation, or wound healing. The seemingly unstoppable development of nanotechnology led to unparalleled, innovative, nanoparticle-based solutions that profoundly improve targeting and camouflage capability, solubility, biocompatibility, penetrability, light conversion efficiency, and PS circulation time. Original research articles, brief reports, and communications offering novel ideas and nano tricks on bypassing biological barriers, reducing dosage and side effects, improving real-time monitoring of drug release and distribution, and maximizing PDT efficiency are welcomed. addition, opinions and reviews dealing with nanotechnology-driven progress in targeted PDT are also eligible for submission to this Special Issue which hopefully will contribute to global efforts towards the inauguration of fully personalized therapies.







IMPACT FACTOR 4.9





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us